Iron Overload
This graph shows the total number of publications written about "Iron Overload" by people in the URMC Research Network by year, and whether "Iron Overload" was a major or minor topic of these publication.
Below are the most recent publications written about "Iron Overload" by people in Profiles.
-
Phatak P, Brissot P, Wurster M, Adams PC, Bonkovsky HL, Gross J, Malfertheiner P, McLaren GD, Niederau C, Piperno A, Powell LW, Russo MW, Stoelzel U, Stremmel W, Griffel L, Lynch N, Zhang Y, Pietrangelo A. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology. 2010 Nov; 52(5):1671-779.
-
Imran F, Phatak P. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes. Expert Rev Pharmacoecon Outcomes Res. 2009 Aug; 9(4):297-304.
-
Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin. 2009 Jan; 25(1):139-47.
-
Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008 Nov; 83(11):858-61.
-
Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM, Deeg HJ, Erba HP, Foran JM, Garcia-Manero G, Gore SD, Head D, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Saba HI, Shami PJ, Spiers K, Stone RM, Tallman MS, Westervelt P. Myelodysplastic syndromes. J Natl Compr Canc Netw. 2008 Oct; 6(9):902-26.
-
Gordeuk VR, Reboussin DM, McLaren CE, Barton JC, Acton RT, McLaren GD, Harris EL, Reiss JA, Adams PC, Speechley M, Phatak PD, Sholinsky P, Eckfeldt JH, Chen WP, Passmore L, Dawkins FW. Serum ferritin concentrations and body iron stores in a multicenter, multiethnic primary-care population. Am J Hematol. 2008 Aug; 83(8):618-26.
-
Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. Am J Hematol. 2008 Apr; 83(4):263-70.
-
Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007 Oct; 47(10):1919-29.
-
Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics. 2007; 25(4):329-42.
-
Sham RL, Raubertas RF, Braggins C, Cappuccio J, Gallagher M, Phatak PD. Asymptomatic hemochromatosis subjects: genotypic and phenotypic profiles. Blood. 2000 Dec 1; 96(12):3707-11.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
|
